Form 8-K - Current report:
SEC Accession No. 0001193125-26-249684
Filing Date
2026-06-01
Accepted
2026-06-01 06:56:36
Documents
14
Period of Report
2026-05-29
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 1.02: Termination of a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d100941d8k.htm   iXBRL 8-K 33244
2 EX-5.1 d100941dex51.htm EX-5.1 10243
3 EX-10.1 d100941dex101.htm EX-10.1 201065
7 GRAPHIC g100941g17t82.jpg GRAPHIC 4470
  Complete submission text file 0001193125-26-249684.txt   432068

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA inab-20260529.xsd EX-101.SCH 3162
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE inab-20260529_lab.xml EX-101.LAB 18735
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE inab-20260529_pre.xml EX-101.PRE 11695
17 EXTRACTED XBRL INSTANCE DOCUMENT d100941d8k_htm.xml XML 3754
Mailing Address EMPIRE STATE BUILDING 350 5TH AVENUE, SUITE 5330 NEW YORK NY 10118
Business Address EMPIRE STATE BUILDING 350 5TH AVENUE, SUITE 5330 NEW YORK NY 10118 (646) 600-6438
IN8BIO, INC. (Filer) CIK: 0001740279 (see all company filings)

EIN.: 825462585 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39692 | Film No.: 261047071
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)